This position paper is based on a one-day workshop held in Berlin on October 1st, 2018. The executive board of the German Society of Epileptology (German Chapter of the ILAE; HMH, MH, TM, ASB) invited members of the Federal Joint Committee (G-BA) (see acknowledgement), the Institute for Quality and Efficiency in Health Care (IQWiG) (TK; see acknowledgement) as well as representatives of patient organizations (SF, KR) and drug manufacturers (see acknowledgement) to discuss future designs of trials in adults on adjunctive treatment with antiseizure drugs serving best the various expectations and requirements they are facing.
15
MAR
MAR
0